Moderna (NASDAQ:MRNA) PT Lowered to $178.00

Moderna (NASDAQ:MRNA) had its price target cut by stock analysts at The Goldman Sachs Group from $204.00 to $178.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 105.59% from the stock’s current price.

A number of other research analysts have also recently issued reports on MRNA. UBS Group raised their price target on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Canaccord Genuity Group raised their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. Oppenheimer raised their target price on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, June 12th. Finally, Royal Bank of Canada raised their target price on shares of Moderna from $135.00 to $160.00 and gave the stock an “outperform” rating in a report on Monday, June 3rd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $126.59.

Moderna Trading Down 8.1 %

NASDAQ MRNA opened at $86.58 on Friday. The company has a fifty day simple moving average of $129.81 and a two-hundred day simple moving average of $115.11. The stock has a market cap of $33.18 billion, a P/E ratio of -5.53 and a beta of 1.67. Moderna has a 12-month low of $62.55 and a 12-month high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.91 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. The business had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business’s quarterly revenue was down 29.9% on a year-over-year basis. During the same quarter last year, the company posted ($3.62) earnings per share. On average, analysts forecast that Moderna will post -7.46 earnings per share for the current year.

Insider Activity

In other news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $121.68, for a total value of $1,825,200.00. Following the sale, the director now owns 2,011,931 shares in the company, valued at $244,811,764.08. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Moderna news, CFO James M. Mock sold 648 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $105,280.56. Following the transaction, the chief financial officer now directly owns 5,726 shares in the company, valued at approximately $930,303.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $121.68, for a total transaction of $1,825,200.00. Following the completion of the transaction, the director now owns 2,011,931 shares in the company, valued at $244,811,764.08. The disclosure for this sale can be found here. Insiders have sold a total of 396,239 shares of company stock worth $55,563,937 over the last 90 days. 15.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Moderna

Several institutional investors and hedge funds have recently bought and sold shares of MRNA. TIAA Trust National Association boosted its position in shares of Moderna by 2.3% during the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock worth $447,000 after purchasing an additional 102 shares during the period. International Assets Investment Management LLC boosted its position in shares of Moderna by 6,528.9% during the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after purchasing an additional 381,808 shares during the period. Allworth Financial LP boosted its position in shares of Moderna by 6.5% during the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares during the period. Cadinha & Co. LLC boosted its position in shares of Moderna by 109.0% during the 4th quarter. Cadinha & Co. LLC now owns 81,838 shares of the company’s stock worth $8,139,000 after purchasing an additional 42,685 shares during the period. Finally, Stratos Wealth Advisors LLC boosted its position in shares of Moderna by 32.3% during the 4th quarter. Stratos Wealth Advisors LLC now owns 4,003 shares of the company’s stock worth $398,000 after purchasing an additional 978 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.